Drug
Aln 6400
Aln 6400: highest development phase Phase 2, developed by Alnylam Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALN-6400 NCT07575308 | Phase 2 | Von Willebrand Disease (VWD) |
| ALN-6400 NCT06659640 | Phase 1/2 | Hereditary Hemorrhagic Telangiectasia |
Latest
Follow Aln 6400 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.